340 related articles for article (PubMed ID: 23682862)
1. Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.
Wiese MD; Rowland A; Polasek TM; Sorich MJ; O'Doherty C
Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1025-35. PubMed ID: 23682862
[TBL] [Abstract][Full Text] [Related]
2. Teriflunomide for the treatment of multiple sclerosis.
Warnke C; Stüve O; Kieseier BC
Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S90-4. PubMed ID: 24321165
[TBL] [Abstract][Full Text] [Related]
3. Teriflunomide for oral therapy in multiple sclerosis.
Papadopoulou A; Kappos L; Sprenger T
Expert Rev Clin Pharmacol; 2012 Nov; 5(6):617-28. PubMed ID: 23234322
[TBL] [Abstract][Full Text] [Related]
4. Recognizing and overcoming potential barriers to oral medications for MS.
Moses H
J Clin Psychiatry; 2014 Oct; 75(10):e28. PubMed ID: 25373133
[TBL] [Abstract][Full Text] [Related]
5. From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.
Aly L; Hemmer B; Korn T
Curr Neuropharmacol; 2017; 15(6):874-891. PubMed ID: 27928949
[TBL] [Abstract][Full Text] [Related]
6. Teriflunomide for the treatment of multiple sclerosis.
Oh J; O'Connor PW
Semin Neurol; 2013 Feb; 33(1):45-55. PubMed ID: 23709212
[TBL] [Abstract][Full Text] [Related]
7. Teriflunomide: a novel oral treatment for relapsing multiple sclerosis.
Sartori A; Carle D; Freedman MS
Expert Opin Pharmacother; 2014 May; 15(7):1019-27. PubMed ID: 24742277
[TBL] [Abstract][Full Text] [Related]
8. [TERIFLUNOMIDE: A NEW ORAL IMMUNOMODULATING AGENT FOR MULTIPLE SCLEROSIS].
Bencsik K; Rózsa C; Vécsei L
Ideggyogy Sz; 2015 Mar; 68(3-4):79-87. PubMed ID: 26434194
[TBL] [Abstract][Full Text] [Related]
9. Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis.
Papadopoulou A; Kappos L; Sprenger T
Expert Opin Drug Saf; 2015 May; 14(5):749-59. PubMed ID: 25687236
[TBL] [Abstract][Full Text] [Related]
10. Teriflunomide (AUBAGIO). Multiple sclerosis: just a metabolite of leflunomide.
Prescrire Int; 2015 Mar; 24(158):61-4. PubMed ID: 25897452
[TBL] [Abstract][Full Text] [Related]
11. Teriflunomide (Aubagio®) for the treatment of multiple sclerosis.
Bar-Or A
Exp Neurol; 2014 Dec; 262 Pt A():57-65. PubMed ID: 24925677
[TBL] [Abstract][Full Text] [Related]
12. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.
Miller AE
Clin Ther; 2015 Oct; 37(10):2366-80. PubMed ID: 26365096
[TBL] [Abstract][Full Text] [Related]
13. [Teriflunomide for treatment of multiple sclerosis].
Warnke C; Meyer Zu Hörste G; Menge T; Stüve O; Hartung HP; Wiendl H; Kieseier BC
Nervenarzt; 2013 Jun; 84(6):724-31. PubMed ID: 23695001
[TBL] [Abstract][Full Text] [Related]
14. Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis.
Chan A; de Seze J; Comabella M
CNS Drugs; 2016 Jan; 30(1):41-51. PubMed ID: 26758290
[TBL] [Abstract][Full Text] [Related]
15. Immune mechanisms of new therapeutic strategies in MS: teriflunomide.
Claussen MC; Korn T
Clin Immunol; 2012 Jan; 142(1):49-56. PubMed ID: 21367665
[TBL] [Abstract][Full Text] [Related]
16. [Teriflunomide is a new peroral disease-modifying drug for multiple sclerosis (a review)].
Boĭko OV; Stoliarov ID; Petrov AM; Boĭko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):78-81. PubMed ID: 24416812
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study.
Qiu W; Huang DH; Hou SF; Zhang MN; Jin T; Dong HQ; Peng H; Zhang CD; Zhao G; Huang YN; Zhou D; Wu WP; Wang BJ; Li JM; Zhang XH; Cheng Y; Li HF; Li L; Lu CZ; Zhang X; Bu BT; Dong WL; Fan DS; Hu XQ; Xu XH;
Chin Med J (Engl); 2018 Dec; 131(23):2776-2784. PubMed ID: 30511679
[TBL] [Abstract][Full Text] [Related]
18. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Comi G; Freedman MS; Kappos L; Olsson TP; Miller AE; Wolinsky JS; O'Connor PW; Benamor M; Dukovic D; Truffinet P; Leist TP
Mult Scler Relat Disord; 2016 Jan; 5():97-104. PubMed ID: 26856952
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
[TBL] [Abstract][Full Text] [Related]
20. [Teriflunomide (Aubagio), oral administration].
J Pharm Belg; 2015 Sep; (3):49-55. PubMed ID: 26513836
[No Abstract] [Full Text] [Related]
[Next] [New Search]
